LOST HEARING; PSORIASIS GOT CYSTIC; KINDA GOT BACK WITH CROHNS AND WHEN PATIENT RECEIVED COVID-19 VACCINE IT CAME OUT WITH VENGEANCE; This spontaneous case was reported by a consumer and describes the occurrence of DEAFNESS (LOST HEARING), CROHN'S DISEASE (KINDA GOT BACK WITH CROHNS AND WHEN PATIENT RECEIVED COVID-19 VACCINE IT CAME OUT WITH VENGEANCE) and PSORIASIS (PSORIASIS GOT CYSTIC) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for an unknown indication, USTEKINUMAB (STELARA) for an unknown indication, TOFACITINIB CITRATE (XELJANZ) for an unknown indication and INFLIXIMAB (REMICADE) for an unknown indication.    Concurrent medical conditions included Crohn's disease and Psoriasis.   In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose., USTEKINUMAB (STELARA) (unknown route) at an unspecified dose, TOFACITINIB CITRATE (XELJANZ) (unknown route) 10 milligram twice a day and INFLIXIMAB (REMICADE) (unknown route) at an unspecified dose. In 2021, the patient experienced CROHN'S DISEASE (KINDA GOT BACK WITH CROHNS AND WHEN PATIENT RECEIVED COVID-19 VACCINE IT CAME OUT WITH VENGEANCE) (seriousness criterion medically significant). On an unknown date, the patient experienced DEAFNESS (LOST HEARING) (seriousness criterion medically significant) and PSORIASIS (PSORIASIS GOT CYSTIC) (seriousness criterion medically significant). At the time of the report, DEAFNESS (LOST HEARING), CROHN'S DISEASE (KINDA GOT BACK WITH CROHNS AND WHEN PATIENT RECEIVED COVID-19 VACCINE IT CAME OUT WITH VENGEANCE) and PSORIASIS (PSORIASIS GOT CYSTIC) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Drug level: did not have any of it in system.         Concomitant Drugs Not Reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. For many years the patient was taking Remicade infusion monthly, then moved Humira and then Stelara, caller spelled drug as Starlar, she only took it for a few weeks because her psoriasis got cystic and she lost her hearing, so she was moved back to Humira, and she was been on it ever since. In 2021, recently things kinda got back with her Chron's, the frequency and pain were terrible and the mucus was awful. She had a test done to check the level of Humira and found out as she did not have any of the Humira in her system. She stated that these drugs were autoimmune-drugs, they stopped working and she was moved to Xeljanz. Since the other drugs were immunosuppressant she was restricted on things, specially about Covid vaccine, she received both doses of the Moderna Covid-19 vaccine however her physician advised her not to receive a booster because she had a bad reaction to it. Every time she had a shot of the Moderna vaccine on Friday and on Monday it was time for her Humira but her Crohn's was came out with vengeance, after a few days it settled down and she was fine until she had the other shot of Moderna and the same thing happened.  No treatment information was provided This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment:  This spontaneous case concerns a female patient of an unknown age with relevant medical history of Crohn's disease and Psoriasis, and concomitant use of Ustekinumab and Tofacitinib citrate, who experienced the unexpected, serious  (medically significant) events of Deafness, Crohn's disease, and Psoriasis (reported as Psoriasis got cystic), that occurred in the context of receiving a dose of mRNA-1273 vaccine. Latency cannot be assessed since vaccination date and onset date of events were not reported.  Outcome of all the events was reported as unknown.  Patient received a total of 2 doses of mRNA-1273 vaccines administered on unspecified dates and at an unknown interval. Crohn's disease and Psoriasis are known to be exacerbated by triggers that that result in flares, while concomitant use of Ustekinumab and Tofacitinib citrate may cause diarrhea as an adverse reaction, thus, could be considered as contributory.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a female patient of an unknown age with relevant medical history of Crohn's disease and Psoriasis, and concomitant use of Ustekinumab and Tofacitinib citrate, who experienced the unexpected, serious  (medically significant) events of Deafness, Crohn's disease, and Psoriasis (reported as Psoriasis got cystic), that occurred in the context of receiving a dose of mRNA-1273 vaccine. Latency cannot be assessed since vaccination date and onset date of events were not reported.  Outcome of all the events was reported as unknown.  Patient received a total of 2 doses of mRNA-1273 vaccines administered on unspecified dates and at an unknown interval. Crohn's disease and Psoriasis are known to be exacerbated by triggers that that result in flares, while concomitant use of Ustekinumab and Tofacitinib citrate may cause diarrhea as an adverse reaction, thus, could be considered as contributory.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.